| Targets |
This compound does not have a defined biological target. It is a synthetic building block used to introduce the triazine scaffold into larger molecules. The final products may target various enzymes or receptors, but the intermediate itself is not biologically active.
|
|---|---|
| ln Vitro |
In vitro, this compound is employed in nucleophilic aromatic substitution and palladium‑catalyzed coupling reactions to generate diverse triazine derivatives. It is also used in the synthesis of kinase inhibitors, antiviral agents, and herbicides. Its chemical reactivity is well suited for library synthesis and medicinal chemistry projects.
|
| ln Vivo |
In vivo, this intermediate is not administered as a therapeutic agent. Its importance is restricted to the chemical synthesis of active compounds. Any in vivo effects are associated with the final products, not with this intermediate.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable. Characterization includes HPLC, NMR, and MS to confirm structure and purity. These methods ensure quality for subsequent reactions.
|
| Cell Assay |
In vitro cellular assays are not performed on this intermediate. It is used only as a precursor. The final compounds may be tested in cell‑based assays for biological activity.
|
| Animal Protocol |
In vivo animal studies are not conducted with this intermediate. It is a research chemical for synthesis, not a drug candidate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not available. Its physical properties, such as melting point and solubility, are characterized for synthetic use.
|
| Toxicity/Toxicokinetics |
The compound is a laboratory chemical and should be handled with care. It may cause irritation. No specific toxicological data are available. It is not for human consumption.
|
| Additional Infomation |
Bromo‑1,2,4‑triazin‑3‑amine is a research intermediate used in the synthesis of triazine‑based pharmaceuticals and agrochemicals. Its versatile reactivity makes it a useful building block. It is not approved for clinical use.
|
| Exact Mass |
173.954
|
|---|---|
| CAS # |
69249-22-5
|
| PubChem CID |
15332564
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
2.0±0.1 g/cm3
|
| Boiling Point |
373.6±34.0 °C at 760 mmHg
|
| Flash Point |
179.7±25.7 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.663
|
| LogP |
-0.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
77.7
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(N=NC(=N1)N)Br
|
| InChi Key |
WIBIPFPOGMLYJQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H3BrN4/c4-2-1-6-3(5)8-7-2/h1H,(H2,5,6,8)
|
| Chemical Name |
6-bromo-1,2,4-triazin-3-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
